drugset / Trial / NCT01848925
Study of SANGUINATE™ Versus Hydroxyurea in Sickle Cell Disease (SCD) Patients
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to compare the safety of SANGUINATE™ versus Hydroxyurea in patients suffering from Sickle Cell Disease.
Timeline
- Start
- 2013-05
- Primary completion
- 2014-07
- Completion
- 2014-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Hydroxyurea | Other / unclassified | 15 mg/kg | — |
| Subject | pegylated carboxyhemoglobin bovine | Protein / enzyme biologic | 40 mg/ml | Intravenous |